Celltrion’s Remsima SC (biosimilar, infliximab) Receives EC’s Approval for Rheumatoid Arthritis

 Celltrion’s Remsima SC (biosimilar, infliximab) Receives EC’s Approval for Rheumatoid Arthritis

Celltrion’s Remsima SC (biosimilar, infliximab) Receives EC’s Approval for Rheumatoid Arthritis

Shots:

  • The approval is based on P-I/III study assessing PK, efficacy and safety of Remsima/CT-P13 SC + MTX vs CT-P13 IV in patients with active RA with inadequate response to DMARDs, results demonstrated that switching patients from Remsima IV to its SC formulation @30wks. is comparable to maintaining Remsima SC up to 54wks.
  • The approval provides patients an opportunity of self-administration to control their own treatment. Remsima SC develops fewer anti-drug antibodies leading to an improvement in treatment for patients with RA
  • Remsima SC is the world’s first SC formulation of infliximab and has received CHMP’s positive opinion with its submission of MAA to EMA for extending its indication to IBD, a decision expected in mid-2020. Celltrion plans to launch Remsima SC across EU in Q1’20

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Reuters

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post